Sudden cardiac death MRI: Difference between revisions
Jump to navigation
Jump to search
/* 2022 ESC Guidelines for the management of patients with ventricular arrythymias and the prevention of sudden cardiac death {{cite journal| author=Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA | display-authors=etal| title=2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. | journal=Eur Heart J | year= 2022 | volume= 43 | issue= 40 | pages= 3997-4126 | pmid=36017572 | doi=10.1093/eurheartj/ehac26... |
|||
| Line 41: | Line 41: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''''' | | colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''''' | ||
|- | |- | ||
| bgcolor="LemonChiffon"| | | bgcolor="LemonChiffon"| | ||
* In [[patients]] with suspected [[premature ventricular complex]] ([[PVC]])-induced [[cardiomyopathy]], [[cardiac magnetic resonance]] | * In [[patients]] with suspected [[premature ventricular complex]] ([[PVC]])-induced [[cardiomyopathy]], [[cardiac magnetic resonance]] ([[CMR]]) should be considered. | ||
|} | |} | ||
| Line 51: | Line 51: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | | colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | ||
|- | |- | ||
| bgcolor="LemonChiffon"| | | bgcolor="LemonChiffon"| | ||
* [[CMR]] with [[LGE]] should be considered in [[dilated cardiomyopathy]] ([[DCM]])/[[hypokinetic non-dilated cardiomyopathy]] ([[HNDCM]]) [[patients]] for assessing the [[etiology]] and the [[risk]] of [[ventricular arryhthmia]] ([[VA]]) | * [[CMR]] with [[LGE]] should be considered in [[dilated cardiomyopathy]] ([[DCM]])/[[hypokinetic non-dilated cardiomyopathy]] ([[HNDCM]]) [[patients]] for assessing the [[etiology]] and the [[risk]] of [[ventricular arryhthmia]] ([[VA]])/ [[sudden cardiac death]] ([[SCD]]). | ||
|} | |} | ||
Revision as of 03:02, 22 July 2023
|
Sudden cardiac death Microchapters |
|
Diagnosis |
|---|
|
Sudden cardiac death MRI On the Web |
|
American Roentgen Ray Society Images of Sudden cardiac death MRI |
|
Risk calculators and risk factors for Sudden cardiac death MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Edzel Lorraine Co, DMD, MD[3]
Overview
Cardiac magnetic resonance imaging (MRI) is an accurate modality for diagnosis of structural and functional causes of cardiac arrest by the evaluation of chamber volumes, left ventricular and right ventricular mass, size and function, and regional wall motion abnormality.
MRI
- Cardiac magnetic resonance imaging (MRI) is an accurate modality for diagnosis of structural and functional causes of cardiac arrest by the evaluation of chamber volumes, left ventricular and right ventricular mass, size and function, and regional wall motion abnormality. [1]
- This imaging identifies presence of myocardial edema, infiltration, fibrosis, and perfusion defects.
2022 ESC Guidelines for the management of patients with ventricular arrythymias and the prevention of sudden cardiac death [2]
| Recommendations for evaluation of patients presenting with newly documented ventricular arryhthmia |
| Class IIa (Level of Evidence: C) |
|
| Recommendations for evaluation of sudden cardiac arrest survivors |
| Class I (Level of Evidence: B) |
|
| Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy |
| Class IIa (Level of Evidence: C) |
|
| Recommendations for evaluation of patients presenting with dilated cardiomyopathy/ hypokinetic non-dilated cardiomyopathy |
| Class IIa (Level of Evidence: B) |
|
2017AHA/ACC/HRS Guideline for management of sudden cardiac arrest and ventricular arrhythmia
| Class IIa (Level of Evidence: C) |
|
References
- ↑ Zareba, Wojciech; Zareba, Karolina M. (2017). "Cardiac Magnetic Resonance in Sudden Cardiac Arrest Survivors". Circulation: Cardiovascular Imaging. 10 (12). doi:10.1161/CIRCIMAGING.117.007290. ISSN 1941-9651.
- ↑ Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA; et al. (2022). "2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". Eur Heart J. 43 (40): 3997–4126. doi:10.1093/eurheartj/ehac262. PMID 36017572 Check
|pmid=value (help). - ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.